Cochrane · systematic review · CD004434
Endothelin receptor antagonists for pulmonary arterial hypertension
Liu, C, Chen, J, Gao, Y, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 28.6%Moderate 5 · 71.4%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Endothelin receptor antagonists compared to placebo for pulmonary arterial hypertension
Population: pulmonary arterial hypertension
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change from baseline in 6MWD (m) mean duration of study 16.3 weeks Endothelin receptor antagonists vs placebo | no estimate extracted | 14 studies · 2739 participants | Moderate Downgraded: risk of bias |
Proportion of participants with improved functional class mean duration of study 16.8 weeks Endothelin receptor antagonists vs placebo | OR 1.41 [1.16, 1.7] | 15 studies · 3060 participants | Moderate Downgraded: risk of bias |
Change from baseline in BDI mean duration of study 14.3 weeks Endothelin receptor antagonists vs placebo | no estimate extracted | 7 studies · 788 participants | Low Downgraded: risk of bias, publication bias |
Mortality mean duration of study 30.2 weeks Endothelin receptor antagonists vs placebo | OR 0.78 [0.58, 1.07] | 12 studies · 2889 participants | Low |
Change from baseline in mean PAP (mmHg) mean duration of study 17.1 weeks Endothelin receptor antagonists vs placebo | no estimate extracted | 8 studies · 729 participants | Moderate |
Change from baseline in PVR (dyn/s/cm5) mean duration of study 15.7 weeks Endothelin receptor antagonists vs placebo | no estimate extracted | 7 studies · 586 participants | Moderate |
Hepatic toxicity mean duration of study 25 weeks Endothelin receptor antagonists vs placebo | OR 1.88 [0.91, 3.9] | 11 studies · 2250 participants | Moderate Downgraded: risk of bias |